Novo Nordisk A/S NOVO-B.CO
Nasdaq Copenhagen · Healthcare · Drug Manufacturers - General
269.45 DKK
−0.7%
2026-11-06
Keep this stock on your watchlist and set email alerts for prices, reports and important announcements where available.
Annual accounts for Novo Nordisk
| DKK million | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 176,954 | 232,261 | 290,403 | 309,064 |
| EBITDA | 76,802 | 114,629 | 137,376 | 149,413 |
| Net income | 55,525 | 83,683 | 100,988 | 102,434 |
| Balance sheet | ||||
| Equity | 83,486 | 106,561 | 143,486 | 194,047 |
| Total debt | 25,784 | 27,006 | 102,787 | 130,958 |
| Cash | 12,653 | 14,392 | 15,655 | 26,464 |
| Net debt | 13,131 | 12,614 | 87,132 | 104,494 |
| Ratios and per share | ||||
| EBITDA margin | 43.4% | 49.4% | 47.3% | 48.3% |
| Profit margin | 31.4% | 36.0% | 34.8% | 33.1% |
| Return on equity | 66.5% | 78.5% | 70.4% | 52.8% |
| Earnings/share (DKK) | 12.34 | 18.77 | 22.74 | 23.05 |
| Book value/share (DKK) | 18.55 | 23.90 | 32.31 | 43.67 |
| Shares outstanding (M) | 4,500 | 4,458 | 4,441 | 4,443 |
From the annual statements (Yahoo Finance), in the currency the company reports in. Per-share figures use the shares at the year end. Charts and annual figures →
Key figures
| P/E | 11.7 |
| P/B | 6.2 |
| EV / EBITDA | 8.7 |
| Net debt / EBITDA | 0.7 |
| Return on equity | 52.8% |
| Profit margin | 33.1% |
| Beta 1Y | 2.16 |
| Revenue growth 1Y | +6.4% |
| Revenue CAGR 3Y | +20.4% |
| Earnings/share CAGR 3Y | +23.2% |
| ROE avg. 3Y | 67.2% |
Ratios use the latest annual report that was public 90 days after the year end.
Dividends per share (DKK)
| 2026 | 11.70 |
| 2025 | 11.65 |
| 2024 | 9.90 |
| 2023 | 7.08 |
| 2022 | 5.58 |
Not investment advice. Figures may contain errors from the data source.